Botensilimab Plus Balstilimab Shows Durable Activity in Refractory CRC Across Lines of Therapy - OncLive

Botensilimab Plus Balstilimab Shows Durable Activity in Refractory CRC Across Lines of Therapy  OncLive ...

Botensilimab,Plus,Balstilimab,Shows,Durable,Activity,in,Refractory,CRC,Across